| __timestamp | Amphastar Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 159205000 | 570979 |
| Thursday, January 1, 2015 | 174172000 | 2185000 |
| Friday, January 1, 2016 | 150976000 | 4554000 |
| Sunday, January 1, 2017 | 149380000 | 3605000 |
| Monday, January 1, 2018 | 187681000 | 5527000 |
| Tuesday, January 1, 2019 | 190434000 | 5234000 |
| Wednesday, January 1, 2020 | 206506000 | 6126000 |
| Friday, January 1, 2021 | 238029000 | 6784000 |
| Saturday, January 1, 2022 | 250127000 | 7592000 |
| Sunday, January 1, 2023 | 293274000 | 11450000 |
Unleashing the power of data
In the competitive world of biopharmaceuticals, understanding cost structures is crucial. Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc. offer a fascinating study in contrasts over the past decade. From 2014 to 2023, Amphastar's cost of revenue surged by approximately 84%, reflecting its expanding operations and market reach. In contrast, Travere Therapeutics, Inc. saw a more modest increase of around 1,900%, albeit from a much smaller base, indicating its growth phase in the industry.
Amphastar's cost of revenue consistently outpaced Travere's, highlighting its established market presence. By 2023, Amphastar's costs were nearly 26 times higher than Travere's, underscoring the scale of its operations. This data not only reveals the financial dynamics of these companies but also provides insights into their strategic priorities and market positioning. As the biopharmaceutical landscape evolves, these trends offer a window into the future of healthcare innovation.
Cost of Revenue Comparison: Zoetis Inc. vs Travere Therapeutics, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Travere Therapeutics, Inc.
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Amphastar Pharmaceuticals, Inc.
BeiGene, Ltd. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Dr. Reddy's Laboratories Limited vs Amphastar Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Catalent, Inc. vs Amphastar Pharmaceuticals, Inc.
Lantheus Holdings, Inc. vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cytokinetics, Incorporated vs Travere Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Amneal Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue Trends: CRISPR Therapeutics AG vs Travere Therapeutics, Inc.
Cost of Revenue Comparison: Perrigo Company plc vs Amphastar Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Amphastar Pharmaceuticals, Inc. and MiMedx Group, Inc.